February 24, 2006 – PsychoGenics Inc. Tarrytown, New York and the Spinal Muscular Atrophy (SMA) Foundation have extended their research agreement to establish and behaviorally phenotype transgenic in vivo models of SMA and test potential therapeutics using these models. As part of this collaborative agreement PsychoGenics has established self-sustaining transgenic SMA colonies and characterized the progression of behavioral and motor deficits in these mice over time. A rapid throughput battery of discriminatory tests has been developed to evaluate candidate drugs and therapies in these models to treat spinal muscular atrophy.